Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer.

Trial Profile

Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 07 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
    • 07 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top